FDA Uses Aborted Babies to Make Mice with Human Immune Systems



A contract signed by The U.S. Food and Drug Administration on July 25 would see to the acquisition of fresh human fetal tissue, and the transplanting of this tissue into mice to give the rodents a human immune system. This information was first published by the FDA and the General Services Administration.

The program, which intends to get its foetal tissues from elective abortions, further explains that the human tissues are needed for implantation into the bodies of mice whose immune systems have been harshly compromised, to create a human immune system in the mice. This program, which was awarded $15,900 contract is being run by Advanced Bioscience Resources (ABR), a San Francisco based organization and will run through to July 25, 2019.

According to CNSNews.com, this move is most likely motivated by a 2016, Harvard University paper clarifying that mice with human immune systems “are engineered to this condition only by means of the use of human fetal material” and that this material can only come from aborted babies not from miscarriages.

Therefore, this begs the question, is the FDA using Federal tax payers’ money to create a demand for aborted babies? Or how does the FDA expect to maintain the demand for aborted human foetus which would be needed for this project? As this project is practically impossible without fresh tissue taken from aborted babies, to what extent would this influence the FDA’s interest in legalised abortion.

CNSNews.com reached out to the FDA with a set of 20 questions seeking to clear up issues concerning this research, the full questions can be found here, the questions mostly sought to find out how the FDA intended to fund a steady supply of aborted babies for their research. The FDA disregarded 17 out of the 20 questions, sending a statement instead that reads:

"The U.S. Food and Drug Administration is committed to ensuring that its research is conducted responsibly, conforms with all legal requirements, and meets the highest ethical standards. At the FDA, research involving human foetal tissue accounts for a very small fraction of the FDA’s total research and has been used in situations where it is critical to understanding how the human immune system responds to certain drugs and biologics. This work has led to a better understanding of a number of conditions and diseases that affect millions of Americans.

"The FDA’s researchers obtain foetal tissue from a non-profit Tissue Procurement Organization (TPO) that have provided assurances that they are in compliance with all applicable legal requirements, including relevant provisions relating to research involving human foetal tissue. FDA is not involved in the TPO’s sourcing of the tissue. "In addition, the FDA has in place systems to ensure FDA research using foetal tissue, as well as any research funded by FDA, is in compliance with applicable federal, state and local regulations and guidelines, as well as FDA policies."

The refusal of the FDA to clear up a majority of the concerns regarding this research leaves the impression that the agency has something to hide and this brings up further questions about the ethical and moral implications of this research.